MediGene AG

Medigene AG (NMarkt: MDG) is a publicly quoted German biopharmaceutical company with Headquarters in Martinsried, Munich, and a subsidiary, Medigene Inc. in San Diego, California. MediGene combines a broad technology platform with products in pre-clinical and clinical development. The company has built up core competence in cardiac and cancer diseases. Founded in 1994, MediGene now has 150 employees (as of December 1, 2001) of which about 80% work in R&D. Around 50% are scientists with a Ph.D.degree.

The Company’s multi-tiered business strategy has generated a number of proprietary enabling technologies to create a portfolio of novel therapeutic opportunities and drug candidates for in-house development and out-licensing.



Based on its successful research work, MediGene has so far developed five fundamental, patented platform technologies. The ITD, CVLP, AAV, HSV and amplicon technologies are the foundation for the development of novel drugs that target the cause of diseases, a resource that can supply the Company’s product pipeline - and those of potential pharmaceutical partners - with new development projects.



Seven products are currently in clinical trials and registration process, the first product launches are expected for 2003. In addition, the product portfolio is to be complemented through strategic in-licensing and potential acquisitions of companies with a strategic fit and complementary technologies.

Contact Details: Lochhamer Strasse 11 Martinsried Bavaria D-82152 Germany Tel: 49 89 89 56 32 0 Fax: 49 89 89 56 32 20 Email: WWW: www.medigene.de/

Recent Publications by MediGene AG:
Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry. Naturally selected T-cell receptors (TCRs) are characterised by low...	6th December, 2007	Avidex Limited (subsidiary of Medigene Ag), 57c Milton Park, Abingdon,	Protein Eng Des Sel. 2007 Aug;20(8):397-403. Epub 2007 Jul 20. DOI Direct Link
Laminar order within Langmuir-Blodgett multilayers from phospholipid and myelin basic protein: a neutron reflectivity study. Multilayers consisting of negatively charged phospholipid DMPA and myelin...	3rd October, 2007	Medigene	Langmuir. 2007 Jul 31;23(16):8491-6. Epub 2007 Jul 6. DOI Direct Link
Extraction and quantification of the cationic lipid 1,2-dioleoyl-3-trimethylammonium propane from human plasma. Multilayers consisting of negatively charged phospholipid DMPA and myelin...	26th May, 2007	MediGene AG, 82152 Martinsried, Germany.	Anal Biochem. 2007 Apr 1;363(1):157-9. Epub 2007 Jan 26. DOI Direct Link
Emerging therapeutic targets in chronic heart failure: part II. Chronic heart failure is characterised by functional deficiencies of the...	2nd May, 2006	Department of Research, MediGene AG, Martinsried, Germany.	Expert Opin Ther Targets. 2003 Feb;7(1):49-59. DOI Direct Link
A new therapeutic approach to treat psoriasis by inhibition of fatty acid oxidation by Etomoxir. BACKGROUND: The dogma in psoriasis is that due to pathogen-induced...	4th February, 2006	Medigene AG, Lochhamerstrasse 11, 82152 Martinsried, Germany.	Br J Dermatol. 2005 Nov;153(5):937-44. DOI Direct Link
→View more MediGene AG research publications.

Press Releases on MediGene AG:
BIO Deutschland: Independent Biotechnology Industry Organisation Founded	1st October, 2004	Bio Deutschland	BIO Deutschland: Independent Biotechnology Industry Organisation Founded 29 October 2004 Berlin - Leading companies from the German biotechnology sector have established a new and independent
SWITCH Biotech appoints new Chief Development Officer for the future	1st April, 2002	Switch	SWITCH Biotech appoints new Chief Development Officer for the future clinical development phases of trial substances Neuried (March 27, 2003
EuropaBio is delighted to partner BIOTECHNICA 2005 and encourages the	1st January, 1970	Europabio	EuropaBio is delighted to partner BIOTECHNICA 2005 and encourages the biotech industry to visit this international trade fair in Hannover this year BIOTECHNICA 2005 (18 - 20 October), 14th

BioNews Results for MediGene AG:
MediGene AG Reports First Nine Months of 2009: Increase in Revenue and Reduction of Loss	Individual.com:  Nov 13 2009 7:11AM Matching: medigene ag
Telormedix Appoints Johanna Holldack as CEO	Pharma Live:  Oct 30 2009 6:13PM Matching: medigene ag
Telormedix Appoints Johanna Holldack as CEO	Bionity.com:  Oct 29 2009 5:22AM Matching: medigene ag
Telormedix Appoints Johanna Holldack as CEO	NewsBlaze:  Oct 27 2009 10:51AM Matching: medigene ag
Telormedix Appoints Johanna Holldack as CEO	Genetic Engineering News:  Oct 27 2009 9:18AM Matching: medigene ag
Promote your company here: BioNewsCast - Press Release Distribution	→View more MediGene AG news.

MediGene AG Patents:
US Patent No.	Title
7556965	Structural protein of adeno-associated virus with modified antigenicity, its production and its use
6207453	Recombinant AAV vector-based transduction system and use of same
6294370	System for the production of AAV vectors
6352696	Papillomavirus truncated L1 protein and fusion protein constructs
6440742	Recombinant AAV vector-based transduction system and use of same
→View more MediGene AG patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 1058 times since April 2007, the link to the organisation's website has been followed 151 times

Recent Search Terms used to find this page: medigene and aav | organisation medigene ag | medigene organisation | medigene | medigene | medigene ag | MediGene AAV | MediGene AAV | Medigene | medigene | .

Search for more companies in Martinsried

Search for more companies in Bavaria

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for MediGene AG